Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen - l'unam - université nantes angers le mans
Journal Articles Clinical Infectious Diseases Year : 2018

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

1 CPTP - Centre de Physiopathologie Toulouse Purpan
2 Laboratoire Virologie [CHU Toulouse]
3 Hôpital Paul Brousse
4 CHU Bordeaux
5 Laboratoire de Virologie [Rennes] = Virology [Rennes]
6 HCL - Hospices Civils de Lyon
7 CHU Saint-Antoine [AP-HP]
8 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
9 CHU Tenon [AP-HP]
10 Centre Hospitalier Universitaire de Rouen
11 CHU de Lille - Centre Hospitalier Universitaire de Lille
12 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
13 Hôpital Henri Mondor
14 CHU Pitié-Salpêtrière [AP-HP]
15 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
16 INSERM UMR-S 606, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, PRES Sorbonne Paris-Cité, and Université Paris Denis Diderot,
17 Laboratoire de Virologie [AP-HP Hôpital Bichat-Claude-Bernard]
18 Service de Virologie [CHRU Nancy]
19 CHU Clermont-Ferrand
20 Service de Virologie [CHU Caen]
21 CHU Angers - Centre Hospitalier Universitaire d'Angers
22 CeRéMAIA - Hôpital André Mignot - Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles]
23 CHU de Grenoble - Centre hospitalier universitaire de Grenoble
24 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
25 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
26 Hôpital Necker
27 Centre Hospitalier Universitaire d'Amiens
28 INSERM - Institut National de la Santé et de la Recherche Médicale
29 UT3 - Université Toulouse III - Paul Sabatier
30 Service d'immunologie clinique et maladies infectieuses [Hôpitaux universitaires CHU Henri Mondor]
31 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Florence Nicot
  • Function : Author
  • PersonId : 906169
Pantxika Bellecave
  • Function : Author
Laurence Morand-Joubert
  • Function : Author
  • PersonId : 972692
Corinne Amiel
  • Function : Author
Magali Bouvier-Alias
  • Function : Author
  • PersonId : 881464
Sidonie Lambert-Niclot
  • Function : Author
  • PersonId : 916115
Vincent Calvez

Abstract

Background. Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t) ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR).Methods. All the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load <50 copies/mL at month 6 with continued suppression at month 12. NGS was performed at baseline (retrospectively) on the 454 GS-FLX platform (Roche).Results. NGS revealed resistance-associated mutations accounting for 1% to <5% of variants in 17.2% of samples, for 5%-20% in 5.7% of samples, and for >20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count <250 cells/mu L at baseline, a slower decrease in viral load at month 3, and rilpivirine resistance at baseline using the Stanford algorithm with a 20% threshold.Conclusions. Minority resistant variants had no impact on the VR of treatment-naive patients to a rilpivirine-based regimen.
Fichier principal
Vignette du fichier
main.pdf (229.37 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-01899957 , version 1 (09-09-2024)

Identifiers

Cite

Stéphanie Raymond, Florence Nicot, Coralie Pallier, Pantxika Bellecave, Anne Maillard, et al.. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clinical Infectious Diseases, 2018, 66 (10), pp.1588 - 1594. ⟨10.1093/cid/cix1070⟩. ⟨hal-01899957⟩
610 View
4 Download

Altmetric

Share

More